The Evolving World of Stem Cells
Devyn Smith, Chief Operating Officer, Sigilon, United States of America

The stem cell industry has evolved rapidly over the last few years as a clinical trials have read out, next generation of therapies have entered the clinic and the science has advanced.

The Genetic Landscape of Hematopoietic Stem Cells
Gregor Adams, Assistant Professor, University of Southern California, United States of America

Elucidating the genetic mechanisms underlying the complex interactions that occur within the hematopoietic stem cell niche requires integrative types of analyses. We are using a highly innovative genome-wide association study approach in mice to identify the genetic factors controlling stem cell physiology.

Recent Advances in Adoptive Immunotherapy of Cancer
Mark Lowdell, Lead Scientist/Director, University College London, United Kingdom

Adoptive cell therapies are part of a whole new breed of medicines and I will discuss how the legislation of these is being applied in Europe and the US. The requirement to use cells and tissues from the patient as starting materials in the drug manufacture is unique in pharmaceuticals and leads to important logistics and regulatory issues as these therapies move into mainstream clinical care.

Single Cell and Subcellular Expression Profiling; Insight into Mechanisms Behind Asymmetric Cell Division
Mikael Kubista, Professor/Founder, TATAA Biocenter AB, Sweden

In my talk I will present the highly robust and powerful experimental and analytical workflows for few and single cells that has been developed and I will also describe the qPCR tomography technique to measure intracellular expression profiles that prepare cells for asymmetric cell division.   

Adult Stem Cells Market Trends
Enal Razvi, Managing Director, Select Biosciences Inc, United States of America

We at SELECTBIO have been continually tracking the cellular therapy space over the past decade. This presentation frames the cellular therapy marketplace both in qualitative and quantitative terms as it exists circa 2014. The data presented is based on our bottom-up market analyses and primary market surveys on large populations of stem cell researchers.

Enabling Cell Manufacturing: a Key Aspect of CCRM's Regenerative Medicine Commercialization Model
Michael May, Chief Executive Officer, Centre for Commercialisation of Regenerative Medicine, Canada

The Centre for Commercialization of Regenerative Medicine is a Canadian-based public/private partnership established to accelerate the development and commercialization of enabling Regenerative Medicine technologies? and cell therapies. Dr. May will present the general CCRM Commercialization model, which encompasses in-house expertise and facilities to optimize and scale cell manufacturing for clinical and commercial production. Industry bottlenecks, plus basic bioengineering principles will be presented with an aim of demonstrating the critical role that bioengineering plays in enabling the emerging cell therapy and regenerative medicine industries.